Compare · VTAK vs WST
VTAK vs WST
Side-by-side comparison of Catheter Precision Inc. (VTAK) and West Pharmaceutical Services Inc. (WST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both VTAK and WST operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- WST carries a market cap of $29.12B.
- Over the past year, VTAK is down 83.7% and WST is up 41.7% - WST leads by 125.3 points.
- VTAK has been more active in the news (8 items in the past 4 weeks vs 4 for WST).
- WST has more recent analyst coverage (15 ratings vs 0 for VTAK).
- Company
- Catheter Precision Inc.
- West Pharmaceutical Services Inc.
- Price
- $0.90-3.09%
- $306.12-1.10%
- Market cap
- -
- $29.12B
- 1M return
- -22.71%
- +23.98%
- 1Y return
- -83.67%
- +41.67%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- AMEX
- NYSE
- IPO
- 2018
- News (4w)
- 8
- 4
- Recent ratings
- 0
- 15
West Pharmaceutical Services Inc.
West Pharmaceutical Services, Inc. designs and produces containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Latest VTAK
- Catheter Precision Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- Catheter Precision Secures U.S. Patent Allowance on Foundational Surgical Technology, Establishing Powerful IP and Accelerating Scalable Growth Strategy
- FLYTE EMERGES AS DIRECT BENEFICIARY AS RISING FUEL COSTS DRIVE AIRLINE RETREAT FROM SHORT-HAUL ROUTES
- VTAK Definitive Agreement to Acquire 100% of Fly Flyte Inc. Obtains Shareholder Approval
- Catheter Precision Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Catheter Precision Announces Accepted Publication in Leading European Medical Journal
- Catheter Precision to Attend the Annual European Heart Rhythm Association Conference
- New LockeT Data Accepted in Leading Electrophysiology Journal
- Catheter Precision Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-K filed by Catheter Precision Inc.
Latest WST
- SEC Form 10-Q filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- West Reports First-Quarter 2026 Results
- West to Host First-Quarter 2026 Conference Call
- SEC Form 4 filed by Haugen Janet Brutschea
- West Expands Dublin Facility to Support High-Volume Injectable Therapies, Including Diabetes and Obesity
- Amendment: SEC Form SCHEDULE 13G/A filed by West Pharmaceutical Services Inc.
- SEC Form DEFA14A filed by West Pharmaceutical Services Inc.
- SEC Form DEF 14A filed by West Pharmaceutical Services Inc.
- West Pharmaceutical Services Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits